U.S. License Holder:
Date of License:
PERJETA (pertuzumab) is a HER2/neu receptor antagonist indicated for:
Use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease;
Use in combination with trastuzumab and chemotherapy as: neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer; adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence.
U.S. Patent LitigationsPACER
U.S. Patent Nos.
7,625,558 (Compositions and Methods of Treating Tumors)
Trustees of The University of Pennsylvania